cdr-life.bsky.social @cdr-life.bsky.social · 16/09/2026CDR-Life will be at the Biotech in Europe Forum in Basel, Oct. 7–8. CFO Konstantin von Schulthess will join a panel on immunology & inflammation, and CBO Sarah Holland will chair the Pharma Strategy & Dealmaking Panel. #CDRLife 010
cdr-life.bsky.social @cdr-life.bsky.social · 09/09/2026Today we announced CDR209, a novel T cell engager for axial spondyloarthritis (axSpA), where significant unmet need remains. Built on our M-gager® platform, CDR209 is designed to target disease-driving TRBV9+ T cells while preserving broader immune function. bit.ly/4xKOHj3 012
cdr-life.bsky.social @cdr-life.bsky.social · 04/09/2026We recently welcomed PhD students and postdoctoral researchers from the Life Science Zurich Young Scientist Network to CDR-Life to talk about careers beyond academia, working in biotech and the many paths into industry. Thanks to everyone who joined us for a great discussion! 010
cdr-life.bsky.social @cdr-life.bsky.social · 31/08/2026CDR-Life is heading to #SITC EU in Lausanne, Sept. 3–4. Leonardo Borras, Dimitrios Chondros, MD, and Melissa Vrohlings will be there to connect and discuss our M-gager platform and highly selective T cell engagers for solid tumors. Reach out to meet the team! 000
cdr-life.bsky.social @cdr-life.bsky.social · 19/08/2026Boston bound! CDR-Life CEO Christian Leisner will attend the Wells Fargo Healthcare Conference, Sept. 8–10. We look forward to connecting with investors and sharing the latest progress across our M-gager® platform and T cell engager pipeline.#WellsFargoHealthcare 010
cdr-life.bsky.social @cdr-life.bsky.social · 07/08/2026Thank you to the Global Entrepreneurial Leadership Program for inviting our Chief Business Officer, @Sarah Holland, to speak with this year's cohort. The discussion explored branding, building momentum and knowing when to scale as a growing biotech company. Great discussion! 010
cdr-life.bsky.social @cdr-life.bsky.social · 10/07/2026The "Life" in CDR-Life isn't only about the patients we hope to impact. It's also about the people behind our science. Last week, our team came together for our annual summer outing. Strong science starts with strong collaboration. #LifeAtCDRLife 000
cdr-life.bsky.social @cdr-life.bsky.social · 09/06/2026Heading to #BIO2026? CDR-Life CBO Sarah Holland will be in San Diego June 22–25 to discuss progress across our M-gager® platform, including CDR404, CDR609 and our expanding autoimmune pipeline. Attending BIO? We'd love to connect. 010
cdr-life.bsky.social @cdr-life.bsky.social · 01/06/2026ASCO is off to a great start. The CDR-Life team is enjoying valuable discussions around next-generation T cell engagers, our Phase 1/2 study of CDR404, and the potential of our M-gager® platform to expand the reach of immunotherapy. If you're attending #ASCO2026, we'd love to connect 000
cdr-life.bsky.social @cdr-life.bsky.social · 21/05/2026CDR-Life and our first-in-class LGR5-targeted M-gager® T cell engager CDR609 featured in BioCentury’s overview of the emerging LGR5 landscape. AACR 2026 data showed encouraging activity in CRC models, including MSS and KRAS mutant tumors. @biocentury.bsky.social www.biocentury.com/article/6595...biocentury.comThe small but diverse LGR5 pipelinePhase III results from Genmab’s first-in-class petosemtamab in head and neck cancer are expected next half, but the bispecific’s LGR5 target ... 000
cdr-life.bsky.social @cdr-life.bsky.social · 20/05/2026CDR-Life CEO Christian Leisner will attend the Jefferies Global Healthcare Conference in New York next month to discuss progress across our M-gager® platform, including CDR404, CDR609 and our autoimmune collaboration with Boehringer Ingelheim. #JefferiesHealthcare 000
cdr-life.bsky.social @cdr-life.bsky.social · 19/05/2026Heading to #ASCO2026! CDR404 is in Phase 1/2 testing for MAGE-A4+ solid tumors, with first-in-human data showing key T cell engager hallmarks. We are also advancing CDR609, our LGR5-targeted T cell engager for solid tumors. Meet the CDR-Life team in Chicago! 000
cdr-life.bsky.social @cdr-life.bsky.social · 11/05/2026Improving lives is part of our mission, including the wellbeing of our own teams. That’s why many colleagues are cycling this May and June as part of the #biketowork initiative. More movement, shared motivation, sustainable commutes! 🚴 000
cdr-life.bsky.social @cdr-life.bsky.social · 05/05/2026Welcome to CDR-Life, Norbu Bargeman, our new scientific intern from the University of Zurich! Outside the lab, Norbu enjoys nature, time with friends, and is a youth leader with Jungwacht Blauring, organizing camps and activities. Glad to have you on board! 010
cdr-life.bsky.social @cdr-life.bsky.social · 22/04/2026Strong scientific engagement at #AACR2026 around our poster on CDR609 our first in class M-gager® T-cell engager targeting LGR5. Valuable discussions on our preclinical data, including LGR5-expressing solid tumor models and approaches to “cold” tumors.Thanks to all who stopped by and to our team! 000
cdr-life.bsky.social @cdr-life.bsky.social · 09/04/2026CMO Leena Gandhi joins a CMO Summit 360° panel on evolving collaboration models to advance new therapies. A timely discussion as the industry rethinks how innovation moves forward. 000
cdr-life.bsky.social @cdr-life.bsky.social · 01/04/2026Great opportunity to join an amazing team! CDR-Life is now hiring a Lab Technician Protein Purification. Learn more: bit.ly/4sbAt6V To apply, please contact: hr@cdr-life.com 000
cdr-life.bsky.social @cdr-life.bsky.social · 23/03/2026CDR-Life achieves first preclinical milestone in its autoimmune collaboration with @Boehringer Ingelheim, advancing a next-generation antibody-based T cell engager designed for selective B-cell depletion. BI has elected to proceed with further development of the candidate. bit.ly/4sXLh9B 022
cdr-life.bsky.social @cdr-life.bsky.social · 17/03/2026Athanasia Dasargyri will present new data on CDR609, a first-in-class T cell engager targeting LGR5+ solid tumors, at #AACR2026. Preclinical studies show strong activity across colorectal cancer subtypes and enhanced effects in combination with cetuximab. #TCellEngagers 031
cdr-life.bsky.social @cdr-life.bsky.social · 17/03/2026Athanasia Dasargyri of CDR-Life will present new data on CDR609, a first-in-class T cell engager targeting LGR5+ solid tumors, at #AACR2026. Preclinical studies show strong activity across colorectal cancer subtypes and enhanced effects in combination with cetuximab. #TCellEngagers 000
cdr-life.bsky.social @cdr-life.bsky.social · 17/03/2026Chief Business Officer Sarah Holland will be in Lisbon, Portugal for BIO-Europe Spring, discussing how CDR-Life's M-gager® platform is redefining what antibody-based T cell engagers can do for solid tumors and autoimmune diseases. Let’s connect! 011
cdr-life.bsky.social @cdr-life.bsky.social · 12/03/2026As part of our Women and Girls in Life Sciences festivities, CDR-Life hosted students from Literargymnasium Rämibühl school. Students received a lab tour and learned about working at a biotech company. It was great seeing the next generation of scientists and company leaders! 010
cdr-life.bsky.social @cdr-life.bsky.social · 10/03/2026Great opportunity to join an amazing team! CDR-Life is hiring a Scientific Intern to gain hands-on experience and contribute to meaningful projects in our fast-moving biotech environment. View the full job description here: www.cdr-life.com/careers/#ope... 110
cdr-life.bsky.social @cdr-life.bsky.social · 09/03/2026Last week at the Sachs Annual European Life Sciences CEO Forum for Partnering and Investment, CBO Sarah Holland moderated a panel on biotech–pharma dealmaking. Thanks to the panelists for a great discussion! 000
cdr-life.bsky.social @cdr-life.bsky.social · 02/03/2026Our CBO Sarah Holland will chair the Pharma Dealmakers Roundtable at the Sachs Associates 19th Annual European Life Sciences CEO Forum with esteemed biotech colleagues. #Sachs_ELSF #DealMaking #Biopharma 020
cdr-life.bsky.social @cdr-life.bsky.social · 27/02/2026Join us at ImmunoMark2026 in London to discuss next-gen precision IO. Biomarker-driven development powers our M-gager® TCE platform. In Phase 1 with CDR404, which is targeting MAGE-A4 in solid tumors, we’re generating translational and PD data to inform dose and patient selection. Let’s connect! 000
cdr-life.bsky.social @cdr-life.bsky.social · 23/02/2026Welcome Polonca Andermann, PhD, as Head of Clinical Operations at CDR-Life. With 20+ years of global oncology trial leadership, she will oversee execution of our M-gager® T cell engager programs and help advance key clinical milestones. We are thrilled you are part of the team, Polonca! 000
cdr-life.bsky.social @cdr-life.bsky.social · 09/02/2026In Scrip’s “What Does 2026 Hold for Biopharma?” Christian Leisner, CEO of CDR-Life, explains why T cell engagers are hitting an inflection point— becoming one of immuno-oncology’s most investable modalities. Read more: bit.ly/4tlZPB3 010
cdr-life.bsky.social @cdr-life.bsky.social · 03/02/2026Dimitrios Chondros, MD, joins the CDR-Life leadership team as Chief Medical Officer. With 20+ years of global oncology and drug development experience, he will lead clinical and translational strategy as we advance our M-gager® platform. Welcome, Dimitrios! Learn more: bit.ly/4qcUPfa 011
cdr-life.bsky.social @cdr-life.bsky.social · 30/01/2026Sarah Holland, Chief Business Officer of CDR-Life and President of Swiss HLG, will join a British-Swiss Chamber of Commerce Zurich Chapter panel with Herbert Smith Freehills Kramer on navigating today’s complex M&A landscape amid geopolitical and market disruption. Register: lnkd.in/dbC79J2a 000
cdr-life.bsky.social @cdr-life.bsky.social · 19/12/2025Warm holiday greetings from the CDR-Life team! As we close out a milestone-filled 2025, we’re grateful for the support of our partners and the biotech community. Wishing you a healthy and successful New Year! 010
cdr-life.bsky.social @cdr-life.bsky.social · 12/12/2025Dr. Matteo Morotti represented CDR-Life in a Citeline roundtable on the future of immuno-oncology, where leaders discussed how bi- and tri-specific antibodies, T-cell engagers and other next-gen modalities are reshaping the landscape. Download! discover.pharmaignite.com/novotech-esm...discover.pharmaignite.comBreaking Through the Checkpoint Blockade in Immuno-Oncology 000
cdr-life.bsky.social @cdr-life.bsky.social · 08/12/2025We’re heading to #JPM2026 to share how our antibody-based M-gager® T cell engagers are opening new paths in solid tumors and autoimmune disease. With emerging first-in-human activity for CDR404 and strong pipeline momentum, we’re excited for the year ahead. Let’s meet! 000
cdr-life.bsky.social @cdr-life.bsky.social · 04/12/2025We will be at ESMO IO talking about our T cell engager (TCE) platform and CDR404, our novel, bispecific and bivalent antibody-derived TCE that targets MAGE-A4. Don’t miss our Phase 1 poster: #ESMOImmuno25 000
cdr-life.bsky.social @cdr-life.bsky.social · 14/11/2025For National Future Day, CDR-Life opened its labs to students eager to learn how medicines are discovered and developed. Partnering with Life Science Cares Switzerland ensures that opportunities like this reach children who might otherwise never see science up close. #Zukunftstag 010
cdr-life.bsky.social @cdr-life.bsky.social · 13/11/2025Chief Business Officer Sarah Holland joins an expert panel at the LSX Informa Investival Showcase, sharing strategies for winning in today’s shifting biopharma and medtech partnering landscape. 011
cdr-life.bsky.social @cdr-life.bsky.social · 04/11/2025Thrilled to expand our partnership w @boehringerglobal.bsky.social to advance CDR111, a trispecific M-gager® designed for broad B-cell depletion in autoimmune diseases. This validates the reach of our antibody fragment–based T-cell engager platform beyond oncology and retinal health. bit.ly/492ru2m 011
cdr-life.bsky.social @cdr-life.bsky.social · 28/10/2025CDR-Life’s Sarah Holland joins #BIOEurope in Vienna to discuss our M-gager® platform, advancing potent, precise T cell engagers for solid tumors and autoimmune diseases. Latest: CDR404 clinical data + CDR609 preclinical results. Let’s meet! 011
cdr-life.bsky.social @cdr-life.bsky.social · 27/10/2025Our team will be in London for #JefferiesHealthcare, sharing how our M-gager® platform is setting a new benchmark for T cell engager precision, unlocking new possibilities in both solid tumors and autoimmune diseases. We welcome the chance to connect! 011
cdr-life.bsky.social @cdr-life.bsky.social · 23/10/2025Early clinical data from CDR404 show all four hallmarks of T cell engager activity in patients with advanced MAGE-A4+ solid tumors, validating the potency of our M-gager® platform and its ability to reach intracellular targets once thought out of reach for antibody-based therapeutics. bit.ly/47Cj00p 010
cdr-life.bsky.social @cdr-life.bsky.social · 13/10/2025CDR-Life is at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics meeting! Join us Oct 23, 12:30–4 pm (Poster Session A, Hall D) for posters on our M-gager® TCEs: • CDR404 – MAGE-A4+ solid tumors • CDR609 – First-in-class LGR5-targeted TCE 111
cdr-life.bsky.social @cdr-life.bsky.social · 11/09/2025Proud to have our CBO Sarah Holland chair the Pharma Strategy & Dealmaking Panel at the #Sachs_BEF alongside leaders from @abbvie.bsky.social, Covington & Burling LLP, GSK, Merck, Novartis and @sobibird.bsky.social 000
cdr-life.bsky.social @cdr-life.bsky.social · 13/08/2025Aug 25–29: Our CBO Sarah Holland joins Biotechgate Digital Partnering to discuss partnering our T cell engagers for solid tumors & autoimmune diseases, and how our M-gager® platform is advancing a highly specific clinical pipeline. Still spots open—reach out to connect! 000
cdr-life.bsky.social @cdr-life.bsky.social · 04/08/2025Meet Romina Doerig, Developability Expert at CDR-Life. She’s spent 4 years assessing molecule stability & solubility to help predict success from discovery to clinic. Her motto: take the chance—you’ll regret the ones you don’t. Fun fact: she never visits the same place twice! 011
cdr-life.bsky.social @cdr-life.bsky.social · 26/06/2025CDR-Life announces CDR609, a novel T-cell engager targeting LGR5—a highly tumor-specific antigen broadly expressed across common solid tumors including colorectal and pancreatic cancer. Built on our M-gager® platform. IND-enabling studies planned for H2 2025. Details: bit.ly/46dO0ne 011
cdr-life.bsky.social @cdr-life.bsky.social · 03/06/2025CEO Christian Leisner talks targeting “clean” cancer antigens with T-cell engagers, early CDR404 data, expansion into autoimmunity (CDR111), Boehringer deal & why Switzerland is ideal for biotech. Full PharmaBoardroom interview: pharmaboardroom.com/interviews/c... 001
cdr-life.bsky.social @cdr-life.bsky.social · 29/05/2025Our CEO Christian Leisner will be at the Jefferies Global Healthcare Conference in NYC next week, sharing how our M-gager® platform is redefining T cell engager precision in solid tumors & autoimmune disease. Connect to learn more. #JefferiesHealthcare 030
cdr-life.bsky.social @cdr-life.bsky.social · 28/05/2025CDR-Life CBO Sarah Holland will be at #BIO2025 in Boston, June 16–19. Learn about our M-gager® platform + T cell engager therapies for cancer & autoimmune disease. Want to meet? Drop us a note. 010
cdr-life.bsky.social @cdr-life.bsky.social · 28/05/2025We’re excited to welcome Pascal Touchon to CDR-Life’s Board. With 40 years in biopharma, including roles at Atara, Ipsen & Novartis, Pascal brings strategic insight, deep industry knowledge and a wide global network —perfectly timed as our first T cell engager progresses in Phase 1. bit.ly/4jqKlpf 011
cdr-life.bsky.social @cdr-life.bsky.social · 23/05/2025A big first for CDR-Life! Our team took on the legendary Sola Stafette relay in Zurich with incredible spirit — on the course and cheering from the sidelines. Still buzzing from the energy, teamwork & fun. Here’s to many more finish lines! #TeamCDRLife #SolaStafette 021
